2015年 主要業績

感染症分野

  • Multicenter Retrospective Study of Cefmetazole and Flomoxef for Treatment of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Bacteremia. Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S.
    Antimicrob Agents Chemother. 2015;59:5107-13.
  • CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic.
    Matsumura Y, Johnson JR, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S; Kyoto-Shiga Clinical Microbiology Study Group.
    J Antimicrob Chemother. 2015;70:1639-49.
  • High prevalence of carbapenem resistance among plasmid-mediated AmpC beta-lactamase-producing Klebsiella pneumoniae during outbreaks in liver transplantation units.
    Matsumura Y, Tanaka M, Yamamoto M, et al.
    Int J Antimicrob Agents. 2015;45:33-40.
  • Development and evaluation of MALDI-TOF MS-based serotyping for Streptococcus pneumoniae.
    Nakano S, Matsumura Y, Ito Y, Fujisawa T et al.
    Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2191-8.